- Home
- ENSG vs LEGN Comparison
ENSG vs LEGN Comparison
Compare ENSG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSG
- LEGN
- Stock Information
- Founded
- ENSG 1999
- LEGN 2014
- Country
- ENSG United States
- LEGN United States
- Employees
- ENSG N/A
- LEGN N/A
- Industry
- ENSG Hospital/Nursing Management
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ENSG Health Care
- LEGN Health Care
- Exchange
- ENSG Nasdaq
- LEGN Nasdaq
- Market Cap
- ENSG 7.3B
- LEGN 7.0B
- IPO Year
- ENSG 2007
- LEGN 2020
- Fundamental
- Price
- ENSG $149.15
- LEGN $28.91
- Analyst Decision
- ENSG Buy
- LEGN Strong Buy
- Analyst Count
- ENSG 7
- LEGN 13
- Target Price
- ENSG $164.71
- LEGN $75.67
- AVG Volume (30 Days)
- ENSG 441.3K
- LEGN 1.7M
- Earning Date
- ENSG 04-29-2025
- LEGN 05-13-2025
- Dividend Yield
- ENSG 0.17%
- LEGN N/A
- EPS Growth
- ENSG 39.72
- LEGN N/A
- EPS
- ENSG 5.30
- LEGN N/A
- Revenue
- ENSG $4,423,354,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ENSG $17.71
- LEGN $64.21
- Revenue Next Year
- ENSG $9.69
- LEGN $53.69
- P/E Ratio
- ENSG $27.22
- LEGN N/A
- Revenue Growth
- ENSG 14.81
- LEGN 112.46
- 52 Week Low
- ENSG $116.23
- LEGN $27.34
- 52 Week High
- ENSG $158.45
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ENSG 78.91
- LEGN 39.95
- Support Level
- ENSG $129.91
- LEGN $28.14
- Resistance Level
- ENSG $133.08
- LEGN $31.12
- Average True Range (ATR)
- ENSG 3.73
- LEGN 1.87
- MACD
- ENSG 1.99
- LEGN -0.16
- Stochastic Oscillator
- ENSG 98.79
- LEGN 25.95
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.